Drugs / S241656
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05786924 | Apr 2023 → Jun 2028 expected | colorectal carcinoma, histiocytic and dendritic cell neoplasm, histiocytosis, metastatic malignant neoplasm in the brain +2 | Servier | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S241656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05786924 ↗ |
| Action | Inhibit | “RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations” NCT05786924 ↗ |
| Route | Oral | “All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study” NCT05786924 ↗ |
| Target | BRAF | “RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations” NCT05786924 ↗ |
| Target | KRAS | “RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations” NCT05786924 ↗ |
| Target | NRAS | “RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations” NCT05786924 ↗ |